Comparative remission rates of schizophrenic patients using various remission criteria

被引:30
作者
Beitinger, Romain [1 ]
Lin, Jingxia [1 ]
Kissling, Werner [1 ]
Leucht, Stefan [1 ]
机构
[1] Tech Univ Munich, Klinikum Rechts Isar, Dept Psychiat & Psychotherapy, D-81675 Munich, Germany
关键词
antipsychotic drugs; remission; response; schizophrenia;
D O I
10.1016/j.pnpbp.2008.06.008
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Rationale: New standardized criteria for remission in schizophrenia were presented in 2005 which need to be examined in regard to their significance for clinical trials. Objectives and methods: Data of six antipsychotic drug trials (n=2463) were analyzed by evaluating the proportion of participants who meet the new remission criteria, their symptomatic components, other criteria for remission and simple response-measures (at least 50% Brief Psychiatric Rating Scale (BPRS) reduction and an at least 50% PANSS reduction or a CGI-severity score of "mild or better"). Results: A total of 23.3%/27.2% (last-observation-carried-forward (LOCF)/completer analysis (CO)) of the patients with positive symptoms at baseline met the severity criteria of remission at 4 weeks, 10.5%/20.3% (worst case/CO) met the severity and time criteria at 28 weeks (three studies) and 10.9%/32.4% (worst case/ CO) met the severity and time criteria at 52 weeks (one study). At 4 weeks 4.5%/5.5% (LOCF/CO) met the severity criteria when a more stringent severity threshold of "very mild or better" was applied. Absence of symptoms was attained only sporadically. The psychotic symptoms component was met by fewer patients than the negative component. The criteria were more stringent than "at least 50% BPRS reduction" and "CGI-severity score not more than mild" and - for the long-term results - than "at least 50% PANSS reduction". In the short-term analysis, the criteria were less stringent than "at least 50% PANSS reduction". Conclusions: The applicability of the severity component of the new criteria in clinical trials was confirmed. The time criterion remains difficult to evaluate. (c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:1643 / 1651
页数:9
相关论文
共 32 条
[1]   Remission in schizophrenia: Proposed criteria and rationale for consensus [J].
Andreasen, NC ;
Carpenter, WT ;
Kane, JM ;
Lasser, RA ;
Marder, SR ;
Weinberger, DR .
AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (03) :441-449
[2]   Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial [J].
Beasley, CM ;
Sanger, T ;
Satterlee, W ;
Tollefson, G ;
Tran, P ;
Hamilton, S ;
Green, A ;
Dott, S ;
Pfister, G ;
Roxas, L ;
Small, J ;
Thomas, M ;
Ames, D ;
Schooler, N ;
Baker, R ;
Levine, R ;
Fabre, L ;
Friedel, R ;
Safferman, A ;
Lieberman, J ;
Stahl, S .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :159-167
[3]   Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial [J].
Beasley, CM ;
Hamilton, SH ;
Crawford, AM ;
Dellva, MA ;
Tollefson, GD ;
Tran, PV ;
Blin, O ;
Beuzen, JN .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1997, 7 (02) :125-137
[4]   The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder [J].
Bouffard, R ;
Hechtman, L ;
Minde, K ;
Iaboni-Kassab, F .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2003, 48 (08) :546-554
[5]   Olanzapine versus ziprasidone: Results of a 28-week double-blind study in patients with schizophrenia [J].
Breier, A ;
Berg, PH ;
Thakore, JH ;
Naber, D ;
Gattaz, WF ;
Cavazzoni, P ;
Walker, DJ ;
Roychowdhury, SM ;
Kane, JM .
AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (10) :1879-1887
[6]   The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone [J].
Buckley, Peter F. ;
Harvey, Philip D. ;
Bowie, Christopher R. ;
Loebel, Antony .
SCHIZOPHRENIA RESEARCH, 2007, 94 (1-3) :99-106
[7]   Remission criteria for schizophrenia: Evaluation in a large naturalistic cohort [J].
De Hert, Marc ;
van Winkel, Ruud ;
Wampers, Martien ;
Kane, John ;
van Os, Jim ;
Peuskens, Joseph .
SCHIZOPHRENIA RESEARCH, 2007, 92 (1-3) :68-73
[8]   Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates [J].
Emsley, Robin ;
Rabinowitz, Jonathan ;
Medori, Rossella .
SCHIZOPHRENIA RESEARCH, 2007, 89 (1-3) :129-139
[9]  
Guy W, 1976, ECDEU Assessment Manual for Psychopharmacology, DOI DOI 10.1037/E591322011-001
[10]   Remission in prognosis of functional outcome: A new dimension in the treatment of patients with psychotic disorders [J].
Helldin, Lars ;
Kane, John M. ;
Karilampi, Ulla ;
Norlander, Torsten ;
Archer, Trevor .
SCHIZOPHRENIA RESEARCH, 2007, 93 (1-3) :160-168